A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a Notice of Allowance from the European Patent Office (EPO).
The stem cell and regenerative medicine company today announced it had received the notice, which is usually sent to an applicant ahead of issuing the patent.
Cynata’s proprietary Cymerus stem cell technology utilises induced pluripotent stem cells and a recently identified precursor cell, known as a mesenchymoangioblast, to achieve the economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs) at commercial scale.
According to the company, its technology has the potential to address the limitations that are inherent in current adult stem cell technologies, such as donor dependence and variability, contamination with non-target cells, and limited scalability.
The patent application is owned by the University of Wisconsin’s Alumni Research Foundation and is among the intellectual property licensed exclusively to Cynata. The inventors on the patent, Dr Maxim Vodyanyk and Professor Igor Slukvin, are also founders of the company.
Cynata said this patent will expand the already strong IP protection of the Cymerus platform. The company also applied for a patent with the Australian Government last month.
“We have a very comprehensive patent portfolio to protect our unique and proprietary IP and will continue to strengthen it with further applications,” Cynata chief executive Dr Ross Macdonald said.
“The ability of the platform to enable manufacture of consistent, high quality mesenchymal stem cell therapeutic products at scale is key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide,” he added.
Cynata has also been trialling the technology in relation to steroid resistant graft-versus-host disease, which is a medical complication that can occur following a bone marrow transplant or tissue graft, where the donated marrow or peripheral blood stem cells attack the recipient’s body, mistakenly identifying it as foreign.
“Our phase I clinical trial in patients with steroid resistant graft-versus-host disease is well underway and with further pre-clinical studies in progress there is significant opportunity to expand our IP,” Dr Macdonald said.
Cynata anticipates the European patent will be granted by mid-September 2018, with an expiration date of 16 March 2031.
Shares in the company were up 3% to A$1.17 by late afternoon trade.